Pneumococcal Infection

  • sponsor
    Merck Sharp & Dohme Corp.
Updated on 18 April 2022


The purpose of this study is to evaluate the concomitant and non-concomitant use of messenger ribonucleic acid (mRNA) mRNA-1273, the nucleoside-modified mRNA vaccine for active immunization to prevent coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), with a 23-valent pneumococcal polysaccharide vaccine for the prevention of pneumococcal disease (V110) and, a 15-valent pneumococcal conjugate vaccine (PCV) indicated for the prevention of invasive pneumococcal disease (V114).


  • Condition: Pneumococcal Infection
  • Clinical Trial Identifier: NCT05158140
  • Sponsor: Merck Sharp & Dohme Corp.
Looking for participants within a 30 mile radius of the study site.

Condition Pneumonia
Clinical Study IdentifierTX290674
SponsorMerck Sharp & Dohme Corp.
Last Modified on18 April 2022


Yes No Not Sure

Inclusion Criteria

Age 50+
Is in good health. Any underlying chronic illness must be documented to be in stable condition
Has received a 2-dose regimen of the Moderna mRNA SARS-CoV-2 vaccine ≥6 months before enrollment

Exclusion Criteria

Has a current or known history of SARS-CoV-2 infection
Has a history of myocarditis and/or pericarditis
Has a known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease
Has a coagulation disorder contraindicating intramuscular vaccinations
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note